<DOC>
	<DOC>NCT02916017</DOC>
	<brief_summary>This study evaluates the long- term safety and effectiveness of adalimumab in participants with non-infectious intermediate-, posterior-, or pan-uveitis in daily practice in Japan.</brief_summary>
	<brief_title>HUMIRAÂ® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participants receiving adalimumab for the treatment of Noninfectious Intermediate, Posterior, or Panuveitis Participants previously treated with adalimumab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-infectious Intermediate-, Posterior-, or Pan-uveitis</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Humira</keyword>
</DOC>